Currently serves as Non-Exec Chairman on the Boards of Tecan Group Ltd and Hill Rom Holdings, Inc. Also serves on the Boards of Catalent Pharma Solutions, Fresenius Medical Care and Perrigo Cornpany.plc. Has previously served on the Boards of a number of Healthcare and Med Tech companies, privately held as well as public. Some of those companies are Millipore, Auxillium, Swedish Orphan International, Prometheus Laboratories, Eurand Pharmaceuticals, Aerocrine and several others.
Mr. Classon was Interim President and CEO of Hillenbrand Industries 2005-2006. Between 1991 to 2004 Mr Classon held a number of key positions within Bayer including Chairman of the Executive Committee of Bayer Healthcare and before that President of Bayer Diagnostics. Prior to Bayer Mr. Classon spent many years in various management roles with Pharmacia in Sweden and the USA.
Mr. Classon holds a Pol.Mag from the University of Gothenburg and an undergraduate degree in Chemical Engineering.
He is managing partner of the LSP Health Economics Fund, a fund investing in medical device, diagnostic and digital health companies. Rudy currently serves on the Board of Directors of Sequana Medical, Curetis, reMYND, Celyad and EMBLEM and has served on many other biotech boards such as Devgen, CropDesign, Ablynx, Actogenix and Multiplicom. Prior to joining LSP, he was one of the co-founders of VIB and co-managing director of this research institute for 17 years, during which he was also responsible for the business development. Under his leadership VIB has built a patent portfolio exceeding 200 patent families, signed 800 R&D and license agreements, spun out twelve companies and laid the foundation for bio-incubators, bio-accelerators and the biotech association FlandersBio. Rudy holds a Ph.D in molecular biology from the University of Ghent where he was also professor innovation management till 2012.
He is the chairman and founder of NeoMed Management in 1997. Prior to that, he has been Chairman and controlling shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized companies in the pharmaceutical, medical device and diagnostic industries. From 1993 to 1997, NeoMed AS co-managed two private equity investment companies, KS Nordic Healthcare Partners and Viking Medical Ventures Limited. He has served as a board member of Clavis Pharma AS, GenoVision AS/Qiagen AS, Thommen Medical AG, Vessix Vascular Inc. and Sonendo Inc., and currently serves on the Board of Directors of JenaValve Technology Inc. and CorFlow Therapeutics AG. He is a founder and former Chairman of the Norwegian Venture Capital Association. He holds a Dr. scient. degree in organic chemistry from the University of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA. He is a Swiss citizen.
Has over 20 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry as General Partner for VI Partners, he has held various managerial positions in the pharmaceuticals and medical devices sectors. In addition to his role in Sequana Medical , Diego presently represents VI Partners in various biotech start-ups companies.
Diego holds a M.Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne.